XVIPF (Xvivo Perfusion AB) PE Ratio: 115.08 (As of Jun. 26, 2026) — 61% Below Median


XVIPF Xvivo Perfusion AB XVIPF
91 GF Score
Price $29.00
GF Value $42.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB PE Ratio?

Xvivo Perfusion AB XVIPF -1.32% 91 PE Ratio is 115.08 as of Jun. 26, 2026, which is 61% below its 10-year median of 297.09. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-26), Xvivo Perfusion AB's share price is $29.0011. Xvivo Perfusion AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25. Therefore, Xvivo Perfusion AB's PE Ratio for today is 115.08.

During the past 13 years, Xvivo Perfusion AB's highest PE Ratio was 11812.50. The lowest was 47.64. And the median was 297.09.

Xvivo Perfusion AB's EPS (Diluted) for the three months ended in Mar. 2026 was $0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25.

As of today (2026-06-26), Xvivo Perfusion AB's share price is $29.0011. Xvivo Perfusion AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25. Therefore, Xvivo Perfusion AB's PE Ratio without NRI ratio for today is 115.08.

During the past 13 years, Xvivo Perfusion AB's highest PE Ratio without NRI was 11812.50. The lowest was 47.64. And the median was 297.09.

Xvivo Perfusion AB's EPS without NRI for the three months ended in Mar. 2026 was $0.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25.

During the past 12 months, Xvivo Perfusion AB's average EPS without NRI Growth Rate was -45.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 8.80% per year.

During the past 13 years, Xvivo Perfusion AB's highest 3-Year average EPS without NRI Growth Rate was 168.90% per year. The lowest was -42.60% per year. And the median was 17.40% per year.

Xvivo Perfusion AB's EPS (Basic) for the three months ended in Mar. 2026 was $0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25.

Back to Basics: PE Ratio


Xvivo Perfusion AB  (OTCPK:XVIPF) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Xvivo Perfusion AB PE Ratio Related Terms


Xvivo Perfusion AB PE Ratio Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB PE Ratio Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 994.64 295.16 107.33 89.89 233.25

Xvivo Perfusion AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.01 80.34 182.32 233.25 97.45

XVIPF vs ABT, SYK, MDT: PE Ratio Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's PE Ratio falls into.


XVIPF
91GF Score
Xvivo Perfusion AB XVIPF
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Xvivo Perfusion AB's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=29.0011/0.252
=115.08

Xvivo Perfusion AB's Share Price of today is $29.0011.
Xvivo Perfusion AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 115.08 mean?
Xvivo Perfusion AB (XVIPF) has a PE Ratio of 115.08 as of Jun. 26, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Xvivo Perfusion AB and its competitors. This is 61% below median its historical median of 297.09. Over the past decade, Xvivo Perfusion AB's PE Ratio has ranged from 47.64 to 11,812.50.
Is Xvivo Perfusion AB's PE Ratio too high?
Xvivo Perfusion AB's current PE Ratio of 115.08 is 61% below median its 10-year median of 297.09. Over the past 10 years, this metric has ranged from a low of 47.64 to a high of 11,812.50. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's PE Ratio compare to ABT and SYK?
Xvivo Perfusion AB's PE Ratio of 115.08 can be compared against companies in the Medical Devices & Instruments industry. Historically, Xvivo Perfusion AB's own PE Ratio has ranged from 47.64 to 11,812.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Devices & Instruments company?
A good PE Ratio depends on the Medical Devices & Instruments industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current PE Ratio is 115.08, which is 61% below median its own 10-year median of 297.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current PE Ratio is 115.08, which is 61% below median its 10-year median of 297.09. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current PE Ratio is 115.08 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • PE Ratio: 115.08 (61% below median its 10-year median of 297.09)
  • GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score

Get the complete analysis for XVIPF

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$42.07
GF Value